Cytochrome P450 1A2 detoxicates aristolochic acid in the mouse.
Aristolochic acids (AAs) are plant-derived nephrotoxins and carcinogens responsible for chronic renal failure and associated urothelial cell cancers in several clinical syndromes known collectively as aristolochic acid nephropathy (AAN). Mice provide a useful model for study of AAN because the renal histopathology of AA-treated mice is strikingly similar to that of humans. AA is also a potent carcinogen in mice with a tissue spectrum somewhat different from that in humans. The toxic dose of AA in mice is higher than that in humans; this difference in susceptibility has been postulated to reflect differing rates of detoxication between the species. Recent studies in mice have shown that the hepatic cytochrome P450 system detoxicates AA, and inducers of the arylhydrocarbon response protect mice from the nephrotoxic effects of AA. The purpose of this study was to determine the role of specific cytochrome P450 (P450) enzymes in AA metabolism in vivo. Of 18 human P450 enzymes we surveyed only two, CYP1A1 and CYP1A2, which were effective in demethylating 8-methoxy-6-nitro-phenanthro-(3,4-d)-1,3-dioxolo-5-carboxylic acid (AAI) to the nontoxic derivative 8-hydroxy-6-nitro-phenanthro-(3,4-d)-1,3-dioxolo-5-carboxylic acid (AAIa). Kinetic analysis revealed similar efficiencies of formation of AAIa by human and rat CYP1A2. We also report here that CYP1A2-deficient mice display increased sensitivity to the nephrotoxic effects of AAI. Furthermore, Cyp1a2 knockout mice accumulate AAI-derived DNA adducts in the kidney at a higher rate than control mice. Differences in bioavailability or hepatic metabolism of AAI, expression of CYP1A2, or efficiency of a competing nitroreduction pathway in vivo may explain the apparent differences between human and rodent sensitivity to AAI.
Rosenquist
Thomas A
TA
Department of Pharmacological Sciences, State University of New York, One Nicolls Road, Stony Brook, NY 11794-8651, USA. rosenquist@pharm.stonybrook.edu
Einolf
Heidi J
HJ
Dickman
Kathleen G
KG
Wang
Lai
L
Smith
Amanda
A
Grollman
Arthur P
AP
D000419:Albuminuria / Q000139:chemically induced / Q000235:genetics; D000818:Animals; D034341:Aristolochic Acids / Q000378:metabolism* / Q000493:pharmacokinetics; D055162:Biocatalysis; D003404:Creatinine / Q000652:urine; D019363:Cytochrome P-450 CYP1A1 / Q000378:metabolism; D019388:Cytochrome P-450 CYP1A2 / Q000235:genetics / Q000378:metabolism*; D018736:DNA Adducts / Q000378:metabolism; D020719:Glucuronides / Q000378:metabolism; D006801:Humans; D008658:Inactivation, Metabolic / Q000235:genetics; D007668:Kidney / Q000187:drug effects / Q000378:metabolism; D007700:Kinetics; D008099:Liver / Q000187:drug effects / Q000378:metabolism; D008297:Male; D008748:Methylcholanthrene / Q000494:pharmacology; D051379:Mice; D008815:Mice, Inbred Strains; D018345:Mice, Knockout; D008862:Microsomes, Liver / Q000187:drug effects / Q000378:metabolism; D051381:Rats; D011994:Recombinant Proteins / Q000378:metabolism
D034341:Aristolochic Acids; D018736:DNA Adducts; D020719:Glucuronides; D011994:Recombinant Proteins; D008748:Methylcholanthrene; C000228:aristolochic acid I; D003404:Creatinine; C504573:CYP1A2 protein, human; D019363:Cytochrome P-450 CYP1A1; D019388:Cytochrome P-450 CYP1A2